CLDF Podcast

Thank you Gilead Sciences, Inc. for your support on this FAQ Video Module. In this thoughtful discussion, Dr. Nancy Reau from RUSH University Medical Center explores the often-overlooked psychological impact of Primary Biliary Cholangitis (PBC). While managing the physical symptoms of PBC is critical, addressing the emotional and mental health challenges faced by patients is equally important. Dr....

Thank you Gilead Sciences, Inc. for your support on this FAQ Video Module. In this insightful discussion, Dr. Tatyana Kushner, hepatologist and associate professor at Weill Cornell Medicine, explores the critical issue of medication adherence in patients living with Primary Biliary Cholangitis (PBC). While ursodeoxycholic acid (ursodiol) remains the cornerstone of first-line therapy for PBC, up to...

Thank you Gilead Sciences, Inc. for your support on this FAQ Video Module. In this engaging update from the Allied Digestive Health Annual Conference, Dr. Sonal Kumar, hepatologist at Weill Cornell Medicine, shares the latest advancements in diagnosing and managing Primary Biliary Cholangitis (PBC). Dr. Kumar emphasizes the importance of early assessment and intervention—highlighting the limitatio...

Thank you Gilead Sciences, Inc. for your support on this FAQ Video Module. In this comprehensive discussion, Hetal Karsan, Chair of Medical Education at United Digestive, explores how to manage complications of Primary Biliary Cholangitis (PBC) and their impact on patient quality of life. PBC is a chronic autoimmune cholestatic liver disease that primarily affects women—but is increasingly diagnos...

Thank you Gilead Sciences, Inc. for your support on this FAQ Video Module. Discover the evolving landscape of Primary Biliary Cholangitis (PBC) treatment with Dr. Huiming Sooki Hon from United Digestive. In this expert-led discussion, Dr. Sooki Hon reviews both established and emerging therapies for PBC, beginning with first-line treatment using ursodeoxycholic acid (UDCA) and the importance of ea...

In this expert spotlight, Dr. Nancy Reau of RUSH University Medical Center addresses two of the most pressing challenges in the management of Primary Biliary Cholangitis (PBC): delayed diagnosis and delayed treatment escalation. Drawing from clinical insights and institutional data, Dr. Reau discusses how symptoms such as fatigue, pruritus, and elevated alkaline phosphatase often go unrecognized f...

In this expert-led video, Dr. Nadege Gunn, a gastroenterologist and hepatologist based in Waco, Texas, offers a practical and up-to-date overview of primary biliary cholangitis (PBC)—a chronic autoimmune liver disease that primarily affects women and can progress to cirrhosis if not treated early. Dr. Gunn breaks down the key steps in diagnosing PBC using simple blood tests, including alkaline pho...

In this video, Dr. Sonal Kumar, hepatologist at Weill Cornell Medical College in New York City, discusses the complex and often debilitating symptoms associated with Primary Biliary Cholangitis (PBC)—a chronic autoimmune liver disease. Dr. Kumar provides expert insight into symptom identification and management strategies for pruritus (itching), fatigue, jaundice, dry eyes and mouth (Sjögren's ove...

In this expert-led video, Dr. Jeff Kahn, hepatologist at the University of Southern California, explores the often-overlooked topic of symptom control and quality of life in primary biliary cholangitis (PBC). Although PBC is a chronic liver disease, symptoms like fatigue and pruritus (itching) can appear early and significantly impact patients’ daily functioning, mental health, and sleep—often ind...

In this episode, Marcelo Kugelmas, MD, and Steven Flamm, MD, discuss strategies to prevent clinical decompensation in patients with cirrhosis and clinically significant portal hypertension. They explore the importance of identifying overlapping liver disease etiologies—such as MASLD/metALD and alcohol-related liver disease—and emphasize a thorough diagnostic approach using non-invasive fibrosis st...

Thank you Madrigal for your support on this podcast episode. Join Dr. Steven Flamm, Rush University Medical School, and Dr. Naim Alkhouri, Arizona Liver Health, for an in-depth discussion on Resmetirom — the first FDA-approved treatment for adults with MASH (Metabolic Dysfunction-Associated Steatohepatitis) and moderate to advanced fibrosis. In this expert-led podcast, the panel explores the groun...

Thank you Madrigal for your support on this Medication Review Video Module. Dr. Reed Hogan, a practicing gastroenterologist in Jackson, Mississippi, shares his clinical experience and insights on Resmetirom, the first FDA-approved therapy for MASH (Metabolic Dysfunction-Associated Steatohepatitis). With over 6,000 patients screened annually in his metabolic and fatty liver clinics, Dr. Hogan highl...

Thank you Madrigal for your support on this Journal Club Video Module. In this expert journal club summary, Dr. Meena Bansal—System Chief for the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai and Director of the MASH Center of Excellence—explains the significance of the newly adopted nomenclature for fatty liver disease. She reviews the multi-society Delphi consensus st...

Thank you Madrigal for your support on this Medication Review Video Module. In this clinical overview, Dr. Kimberly Brown, Associate Medical Director for Liver Transplantation at Henry Ford Hospital, provides a comprehensive update on Resmetirom — the first FDA-approved therapy for adults with MASH (Metabolic Dysfunction-Associated Steatohepatitis) and moderate to advanced fibrosis (F2–F3). Dr. Br...

Thank you Madrigal for your support on this FAQ Video Module. In this insightful video, Dr. Kimberly Brown, Associate Medical Director for Liver Transplantation at Henry Ford Hospital, breaks down the current understanding of disease progression in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH). Dr. Brown r...

Thank you Madrigal for your support on this FAQ Video Module. In this expert update, Dr. Kimberly Brown, Associate Medical Director for Liver Transplantation at Henry Ford Hospital, discusses Resmetirom—the first and only FDA-approved treatment for Metabolic Dysfunction-Associated Steatohepatitis (MASH). Resmetirom is a thyroid hormone receptor beta (THR-β) agonist that targets the liver to reduce...

Thank you Madrigal for your support on this FAQ Video Module. In this expert-led educational video, Dr. Kimberly Brown—Professor of Medicine at Wayne State University and Michigan State University and Transplant Hepatologist at Henry Ford Hospital—breaks down the stages of MASH progression, from early steatosis and inflammation to advanced liver fibrosis and cirrhosis. Dr. Brown explains how untre...

Thank you Intercept for your support of this podcast episode. Welcome to the eighth and final episode of the GHAPP CLDF PBC Podcast Series, hosted by Andrea Gossard, ARNP. In this powerful conclusion to our educational journey on Primary Biliary Cholangitis (PBC), we shift focus toward a holistic approach to PBC management, emphasizing lifestyle modifications, integrative medicine, symptom relief,...

Thank you Intercept for your support of this podcast episode. Welcome to another episode of the GHAPP CLDF PBC Podcast Series, hosted by Andrea Gossard, NP. In this episode, we explore one of the most challenging aspects of Primary Biliary Cholangitis (PBC): identifying progression rates and implementing timely, personalized management strategies. Andrea is joined by fellow GHAPP member and hepato...

Thank you Intercept for your support of this podcast episode. Welcome to Episode 7 of the GHAPP CLDF PBC Podcast Series, hosted by Andrea Gossard, NP. In this pivotal episode, we explore the cumulative impact of nonresponse to ursodeoxycholic acid (UDCA) in patients with Primary Biliary Cholangitis (PBC). Andrea is joined by Anne Moore, NP, a GHAPP board member and expert in PBC management, to dis...

Thank you Intercept for your support of this podcast episode. Welcome to the CLDF GHAPP PBC Podcast Series! In this episode of our eight-part series, host Andrea Gossard, NP, is joined by Christina Hanson, FNP and CLDF GHAPP board member, to explore the evolving role of biomarkers in the diagnosis, monitoring, and personalized treatment of Primary Biliary Cholangitis (PBC). Together, they examine...

Thank you Intercept for your support of this podcast episode. Welcome to the CLDF/GHAPP PBC Podcast Series. In this episode, Dr. Kimberly Brown, Associate Medical Director at Henry Ford Hospital in Detroit, Michigan, is joined by Dr. Sonal Kumar, Assistant Professor of Medicine and Director of Clinical Hepatology at Weill Cornell in New York City. Together, they explore the real-world management o...

Thank you Intercept for your support of this podcast episode. In this episode of the CLDF/GHAPP PBC Podcast Series, Dr. Kimberly Brown, Professor of Medicine at Henry Ford Hospital in Detroit, Michigan, and Dr. Sonal Kumar, Assistant Professor and Director of Clinical Hepatology at Weill Cornell Medicine in New York City, explore how clinical practice is evolving when it comes to earlier intervent...

Thank you Intercept for your support of this podcast episode. In this episode of the CLDF GHAPP PBC Podcast Series, Dr. Kimberly Brown joins Dr. Steven Flamm for an important discussion on building a sense of urgency around evaluating and monitoring patients with Primary Biliary Cholangitis (PBC). Together, they explore how clinical practice has evolved to recognize the variability and unpredictab...

Thank you Intercept for your support of this podcast episode. Welcome to the CLDF GHAPP PBC Podcast Series. In this episode, Dr. Kimberly Brown is joined by Dr. Steven Flamm for an in-depth discussion on primary biliary cholangitis (PBC). Together, they explore the unpredictable progression of PBC to fibrosis and cirrhosis, offering real-world insights into how liver disease develops even in patie...